Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-10-09 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于2023年第三季度健帆转债转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (健帆转债) of 健帆生物科技集团股份有限公司 for the third quarter of 2023. It details the bond issuance, listing, conversion price adjustments, and the fact that no conversions occurred in Q3 2023. It also provides updated shareholding and bond structure information as of September 30, 2023. The document is a formal announcement of bond conversion status and share capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data about bond and share changes. The content fits best under Capital/Financing Update (CAP) as it relates to convertible bond conversion and capital structure updates.
2023-10-09 Chinese
独立董事关于第五届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting decision about terminating an investment project. It references compliance with regulatory rules and company governance documents but does not contain financial statements or detailed financial data. The content is related to board/management information about a corporate decision. The document length is short and focused on a board matter, not a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG).
2023-09-28 Chinese
第五届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the seventh meeting of the fifth Supervisory Board of the company. It details the meeting attendance, the agenda item discussed, and the voting results regarding the termination of a specific investment project. It references compliance with company law and stock exchange listing rules, and it directs readers to a separate announcement for more details. The document is not a full financial report, audit, or earnings release, nor is it a call transcript or investor presentation. It is a regulatory announcement about a board-level decision, specifically from the Supervisory Board, which is part of management/board information. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and content do not suggest it is a report publication announcement or regulatory filing fallback. Confidence is high due to clear meeting and resolution details.
2023-09-28 Chinese
第五届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 健帆生物科技集团股份有限公司. It details the date and attendance of the board meeting, the agenda discussed, and the voting results on a specific project termination. There is no financial data, earnings information, or detailed report content. The document focuses on board decisions and management actions, specifically the termination of a project and the approval by the board. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short and it is not a report or a regulatory filing of financial results or audit information. Therefore, the classification is MANG with high confidence.
2023-09-28 Chinese
关于终止健帆集团医疗器械产业（血液净化设备）项目的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company regarding the termination of an external investment project related to a medical device industry project. It details the board meeting resolutions, the termination agreement, and the impact on the company. The document is relatively short (1974 characters) and focuses on a corporate action announcement rather than financial results or detailed financial data. It does not contain financial statements or detailed financial analysis. It is not a full annual or interim report, nor an earnings release. It is not a regulatory certification or officer attestation. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate decision that does not fit other specific categories like M&A, capital changes, or management changes.
2023-09-28 Chinese
关于奋斗者二号员工持股计划购买完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of an employee stock ownership plan's purchase of company shares. It details the number of shares bought, the total amount spent, and the lock-up period. There is no financial report, earnings data, or detailed analysis. The document is a formal disclosure of a capital-related transaction (employee stock purchase) and does not constitute a full financial report or earnings release. It fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-09-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.